

1 Quality of care when using a digital clinical decision support
2 algorithm to manage sick children at primary care health
3 facilities in Tanzania: a cross-sectional cluster randomized
4 controlled trial (DYNAMIC study)

5

6 Rainer Tan^{1,2,3,4¶*}, Godfrey Kavishe^{5¶†}, Alexandra V Kulinkina^{3,4}, Sabine Renggli², Lameck B Luwanda²,
7 Chacha Mangu⁵, Geoffrey Ashery², Margaret Jorram², Ibrahim Evans Mtebene², Peter Agrea⁵,
8 Humphrey Mhagama⁵, Kristina Keitel^{3,4,6}, Marie-Annick Le Pogam¹, Nyanda Ntinginya^{5&}, Honorati
9 Masanja^{2&}, Valérie D'Acremont^{1,3,4&}

10

- 11 1. Centre for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne,
12 Switzerland
13 2. Ifakara Health Institute, Dar es Salaam, United Republic of Tanzania
14 3. Swiss Tropical and Public Health Institute, Allschwil, Switzerland
15 4. University of Basel, Basel, Switzerland
16 5. National Institute of Medical Research – Mbeya Medical Research Centre, Mbeya, United
17 Republic of Tanzania
18 6. Pediatric Emergency Department, Department of Pediatrics, University Hospital Bern, Bern,
19 Switzerland

20 *Corresponding author

21 E-mail: rainer.tan@unisante.ch

22

23 ¶These authors contributed equally to this work.

24 &These authors also contributed equally to this work.

25 †Deceased

26

27 **Abstract**

28 Digital clinical decision support tools have contributed to improved quality of care at primary care
29 level health facilities. However, data from real-world randomized trials are lacking.

30 We conducted a cluster randomized, open-label trial in Tanzania evaluating the use of a digital
31 clinical decision support algorithm (CDSA), enhanced by point-of-care tests, training and mentorship,
32 compared with usual care, among sick children 2 to 59 months old presenting to primary care
33 facilities for an acute illness in Tanzania (ClinicalTrials.gov NCT05144763). The primary outcome was
34 the mean proportion of 14 major Integrated Management of Childhood Illness (IMCI) symptoms and
35 signs assessed by clinicians. Secondary outcomes included antibiotic prescription, counselling
36 provided, and the appropriateness of antimalarial and antibiotic prescriptions.

37 A total of 450 consultations were observed in 9 intervention and 9 control health facilities. The mean
38 proportion of major symptoms and signs assessed in intervention health facilities was 46.4% (range
39 7.7% to 91.7%) compared to 26.3% (range 0% to 66.7%) in control health facilities, an adjusted
40 difference of 15.1% (95% confidence interval [CI] 4.8% to 25.4%). Only weight, height, and pallor
41 were assessed more often when using the digital CDSA than in controls. Observed antibiotic
42 prescription was 37.3% in intervention facilities, and 76.4% in control facilities (adjusted risk ratio
43 0.5; 95% CI 0.4 to 0.7; $p < 0.001$). Appropriate antibiotic prescription was 81.9% in intervention
44 facilities and 51.4% in control facilities (adjusted risk ratio 1.5; 95% CI 1.2 to 1.8; $p = 0.003$).

45 The implementation of a digital CDSA improved only slightly the mean proportion of IMCI symptoms
46 and signs assessed in consultations with sick children, and most symptoms and signs were assessed
47 infrequently. Nonetheless, antibiotics were prescribed less often, and more appropriately
48 Innovative approaches to overcome barriers related to clinicians' motivation and work environment
49 are needed.

50 **Introduction**

51 Millions of preventable deaths are attributed to suboptimal healthcare quality [1]. Factors such as
52 staff shortages, inadequate budget allocation, poor clinical knowledge, and limited access to quality
53 medical education, mentorship and supervision collectively contribute to this issue [2-4]. In response
54 to this challenge, and with the aim of reducing childhood mortality, the World Health Organization
55 developed the Integrated Management of Childhood Illness (IMCI) Chartbook [5]. Since its inception,
56 over 100 countries have implemented the guidelines, and IMCI may reduce mortality and improve
57 quality of care [6, 7]. However, poor adherence to IMCI is common, limiting its benefits [8-10].

58 Digital Clinical Decision Support Algorithms (CDSAs) were devised with the aim of enhancing
59 adherence to clinical guidelines. These tools, typically operating on electronic tablets or mobile
60 phones, guide health providers through the consultation process, by prompting the evaluation of
61 symptoms, signs, and recommended diagnostic tests, to finally propose the appropriate diagnosis
62 and treatment [11, 12]. While several studies have found that using these digital CDSAs improve
63 adherence to IMCI, it is noteworthy that many of these investigations were conducted in controlled
64 study settings, and most lacked randomization [13-20].

65 ePOCT+, a digital CDSA, was developed based on insights from two previous generations of CDSAs
66 [21, 22], specifically addressing challenges by our CDSAs and others, such as limited scope and
67 information technology difficulties [23]. The aim of the present study was to assess whether this
68 CDSA associated with point-of-care tests, training, and mentorship, would improve quality of care
69 for sick children compared to usual care, by comparing adherence to IMCI in a pragmatic cluster
70 randomized trial.

71

72 **Methods**

73 **Study design**

74 The present study is an open-label, parallel-group, cross-sectional cluster randomized trial within the
75 DYNAMIC Tanzania project. An external clinical researcher observed a sample of consultations from
76 health facilities from both study arms documenting adherence of health care providers to quality-of-
77 care indicators. The study was a planned ancillary study within a larger cluster randomized trial that
78 was conducted between 1 December 2021 and 31 October 2022 using a sample of the clusters [24].
79 A cluster design was chosen since the intervention was targeted at the health facility and healthcare
80 provider. The trial design and rationale are outlined in the protocol available in the parent trial
81 registration on ClinicalTrials.gov number NCT05144763 and in the supplementary materials (S1 File).
82 The detailed statistical analysis plan for this ancillary study is also available in the supplementary
83 materials (S2 File).

84 The study design and implementation were collaboratively executed between both Tanzanian
85 (Ifakara Health Institute, National Institute for Medical Research - Mbeya Medical Research Centre)
86 and Swiss (Centre for Primary Care and Public Health [Unisanté] – University of Lausanne, and Swiss
87 Tropical and Public Health Institute) partners. The design was guided by input from patients, and
88 health providers during the implementation of similar trials in Tanzania [14, 22, 25]. Over 100
89 community engagement meetings involving over 7,000 participants were conducted before and
90 during the study. These meetings included discussions with Community and Regional Health
91 Management Teams in Tanzania.

92

93 **Participants**

94 The health facility was the unit of randomization since the intervention targeted both the healthcare
95 provider and health facility. Primary care health facilities (dispensaries or health centres) were
96 eligible for inclusion if they performed on average 20 or more consultations with children 2 months

97 to 5 years per week, were government or government-designated health facilities, and were located
98 less than 150 km from the research institutions. Specific to this study, consultations were only
99 included if healthcare providers had been trained to use ePOCT+, and the ePOCT+ tool was
100 functioning on the day of observation (no IT issues related to power outages, or crashes reported).

101 In contrast to the larger trial that included children aged 1 day to 14 years, this ancillary study
102 included only children aged 2 to 59 months old presenting for an acute medical or surgical condition
103 at participating health facilities. Children presenting solely for scheduled consultations for a chronic
104 disease (e.g. HIV, tuberculosis, malnutrition), for routine preventive care (e.g. growth monitoring,
105 vaccination), or for a follow-up consultation were excluded.

106 The study was conducted in 5 councils within the Mbeya and Morogoro regions of Tanzania, with
107 two councils being semi-urban and three rural. Malaria prevalence in febrile children was low in
108 three councils, and moderately high in two. HIV prevalence among children less than 5 years old in
109 Tanzania is 0.4% [26]. Healthcare for children under 5 years of age is free for all acute illnesses at
110 government or government-designated primary health facilities, including the cost of medications
111 [27]. Nurses and clinical officers routinely provide outpatient care in dispensaries, while in health
112 centers medical doctors sometimes provide care as well. Clinical Officers, the predominant
113 healthcare providers at primary health facilities, are non-physician health professionals with 2-3
114 years of clinical training following secondary school [28].

115

116 **Interventions**

117 The intervention involved equipping health facilities with ePOCT+, an electronic clinical decision
118 support algorithm on an Android based tablet (Fig 1), along with associated point-of-care tests (C-
119 Reactive Protein, Hemoglobin, pulse oximetry), training, and mentorship. ePOCT+ prompts the
120 healthcare provider to answer questions about demographics, symptoms, signs, and tests [23].
121 Based on the answers, ePOCT+ proposes one or more diagnoses, treatments, and management

122 plans, including referral recommendation. Healthcare providers had the possibility to deviate from
123 ePOCT+ recommendations. In order to move forward within the different sections of the digital tool,
124 it was mandatory to respond to all IMCI symptoms and signs, except for height and mid-upper arm
125 circumference (MUAC) which was optional. The tool allowed some signs to be estimated
126 (temperature, respiratory rate) or based on recent measurements (weight).

127 **Figure 1: Screen-shots of different stages of ePOCT+ running on the medAL-reader application.**

128 Stages are shown in order of appearance, however not all stages are shown in the figure.

129 The implementation team provided mentorship to intervention health facilities. This mentoring
130 consisted of regular visits to health facilities every 2-3 months, and frequent communication via
131 phone calls or group messages (3-4 times per month) to address issues, offer guidance, and gather
132 feedback on the new tools. Quality-of-care dashboards were shared through group messages,
133 enabling healthcare providers to compare their antibiotic prescription rates, uptake, and other
134 quality-of-care indicators with other facilities (benchmarking). Control health facilities continued
135 with usual care, did not have access to clinical data dashboards, and only received visits from the
136 implementation team to help resolve issues related to the electronic case report forms (eCRFs).

137 The infrastructure provided to all health facilities (control and intervention) included a tablet for
138 each outpatient consultation room, a router, a local server (Raspberry Pi), internet connectivity, and
139 backup power (battery or solar system if needed). If unavailable weighing scales, mid-upper arm
140 circumference (MUAC) bands, and thermometers were provided to all health facilities. Healthcare
141 providers from both intervention and control facilities underwent equivalent clinical refresher
142 training on IMCI and concepts of antibiotic stewardship. Additionally, specific training was provided
143 on the use of the ePOCT+ CDSA in intervention facilities and the use of the eCRF in control facilities.

144 **Outcomes**

145 The primary outcome was the mean proportion of 14 pre-identified major IMCI symptoms and signs
146 assessed by the healthcare provider, as observed by an external clinical research assistant. The
147 included symptoms were fever, cough or difficult breathing, convulsions in this illness, diarrhea, ear
148 pain or discharge, child unable to drink or breastfeed, and child vomits everything. The included
149 signs were measurement of temperature, respiratory rate, pallor, weight, mid-upper arm
150 circumference (MUAC), height, and skin turgor. In specific circumstances, some patients were not
151 included in the denominator for specific signs as they were not clinically indicated as defined by
152 IMCI: they include MUAC in children less than 6 months old, respiratory rate in the absence of cough
153 or difficult breathing, and skin turgor in the absence of diarrhea. If cough or difficult breathing was
154 not assessed, then we took the most conservative approach assuming that respiratory rate should
155 have been measured, and the same for diarrhea and skin turgor. Of note “lethargic and
156 unconscious” was considered as assessed if the clinician asked the caregiver if it was present during
157 the illness, and not based on observation of the child as being “lethargic or unconscious”.

158 Secondary outcomes include the proportion of consultations during which each major IMCI
159 symptom and sign were assessed, proportion of which other symptoms and signs were assessed
160 (Supplementary Material Note 1), proportion of consultations where different IMCI counselling was
161 conducted, and proportion of consultations for which antibiotics were prescribed. The rationale for
162 the distinction between “major” IMCI and “other” symptom and signs are described in detail in the
163 statistical analysis plan (Supplementary Material Note 1). Prescription of antibiotics was assessed by
164 the research assistant by observing the actual prescription prescribed. The appropriateness of
165 antibiotic prescription in relation to the retained diagnosis were also assessed. An appropriate
166 antibiotic prescription was a prescription if one of the retained diagnoses required an antibiotic as
167 per IMCI or the WHO hospital pocket book, and the absence of a prescription if no diagnosis
168 required an antibiotic [29, 30]. An appropriate antimalarial prescription was a prescription of any
169 antimalarial if there was a positive malaria test. Assessment of appropriateness was conducted blind
170 to the study arm.

171 All outcomes pertained to the cluster level (health facility), and were assessed by an external clinical
172 research assistants who observed the consultations in the consultation room without interfering
173 with the consultation. The external clinical research assistants were clinical officers with experience
174 in primary care consultations for children. Data was collected using a structured and pre-tested
175 observation form programmed on ODK, and collected on an Android-based tablet. The observation
176 form was based on the 2012 DHS Service Provision Assessment Survey form [31]. Of note, a more
177 recent modification to this survey was developed after the initial planning of this study [31].
178 Modifications were made to the survey form, to shorten the duration of the evaluation and align it
179 more closely with the aim of the evaluation, to incorporate additional signs and symptoms in line
180 with IMCI 2014 guidelines such as duration of symptoms and the symptomatic assessment of
181 lethargic or unconscious, and additions used by similar evaluations conducted previously [17].
182 Initially, antibiotic prescription was considered a co- primary outcome alongside the current primary
183 outcome (proportion of 14 major IMCI symptoms and signs), but was later reclassified as a
184 secondary outcome. We made this change to focus the analysis on quality of care, given that
185 antibiotic prescription was already the primary outcome of the large longitudinal cluster randomized
186 trial [24].

187

188 **Sample size**

189 The original sample size calculation was based on the previous co-primary outcome of antibiotic
190 prescription. To detect a 25% absolute decrease in mean antibiotic prescription from a baseline of
191 50%, using an intraclass correlation coefficient (ICC) of 0.10 and an alpha of 0.05, a sample size of 25
192 patients in 9 clusters (health facilities) per arm was required to have 80% power. The ICC was based
193 on studies evaluating prescription variations among different health care facilities/practices, ranging
194 from 0.07 to 0.10 [32-35].

195 Expecting a high variability in baseline values of symptoms and signs assessed by a clinician and
196 between clinicians [8, 13, 17, 36], the above sample size would have 67-93% power to detect a 30%
197 absolute increase in the assessment of major IMCI symptoms and signs, considering a baseline value
198 of 40-60%, an ICC of 0.15 – 0.25, and an alpha of 0.05.

199

200 **Randomization**

201 Within the parent trial, health facilities were randomized 1:1 by an independent statistician,
202 stratified by monthly attendance, type of health facility (dispensary or health centre), region, and
203 council [37]. For the present ancillary study, another independent statistician sampled 18/40
204 facilities to be included. This included 8/8 health centers (4 intervention, and 4 control), and 10/32
205 dispensaries. Among the 32 dispensaries, 10 were randomly sampled, stratified by study arm and
206 region (following the same 3:2 ratio in favor of the Morogoro region as done in the parent trial). Due
207 to the nature of the intervention, it was not feasible to blind the healthcare providers, patients,
208 study implementers, or external clinical research assistants (observers) to the intervention.

209 A convenience sampling was employed, whereby the external clinical researcher observed all eligible
210 consultations while present at the health facility during normal standard working hours (Monday to
211 Friday, 8:00 to 15:00).

212

213 **Statistical methods**

214 All analyses were performed using an intention-to-treat approach, i.e. all children with a recorded
215 outcome were included in the analysis regardless if the intervention, ePOCT+, was used or not. All
216 analyses were performed using a clustered-level analysis approach instead of an individual-level
217 analysis due to the small number of clusters included [38, 39]. The analysis was performed using a

218 two-stage approach as outlined by Hayes et al [39, 40], to adjust for both the cluster-level and
219 individual-level covariates. In the first stage, we used a logistic regression model for binary outcomes
220 and linear regression model for continuous outcomes adjusting for covariates and ignoring clustering
221 and trial arm. Cluster-level residuals were then calculated for each cluster. In the second stage the
222 residuals were compared to estimate risk ratios for the binary outcomes and mean risk difference
223 for the continuous outcome (including the primary outcome) between study arms. Pre-specified
224 cluster level covariates were type of health facility, council, healthcare worker cadre, and healthcare
225 worker years of experience. Pre-specified individual level covariates of patients were age and sex. All
226 analyses were performed using Stata v16, v17, and v18.

227

228 **Ethics**

229 Written informed consent was obtained from all parents or guardians of participants when attending
230 the participating health facility during the enrollment period. We also requested, written informed
231 consent from all healthcare providers for which their consultations were observed during this
232 ancillary study. Ethical approvals were granted from the Ifakara Health Institute (IHI/IRB/No: 11-
233 2020), the Mbeya Medical Research Ethics Committee (*SZEC-2439/R.A/V.1/65*), the National
234 Institute for Medical Research Ethics Committee (NIMR/HQ/R.8a/Vol. IX/3486 and
235 NIMR/HQ/R.8a/Vol. IX/3583) in Tanzania and from the cantonal ethics review board of Vaud (CER-
236 VD 2020-02800) in Switzerland.

237 **Results**

238 **Baseline characteristics of health facilities, health providers, and**
 239 **patients**

240 Between 23 March 2022 to 3 June 2022, 225 consultations were observed in 9 intervention facilities,
 241 and 225 consultations in 9 control facilities (Fig 2). Type of health facility, urban/rural localization,
 242 and region was well distributed between study arms (Table 1). A total of 17 healthcare providers saw
 243 patients in the control arm, and 22 in the intervention arm during the study. Distribution of sex, age,
 244 working experience and cadre of healthcare providers were similar in study arms. The number of
 245 healthcare providers with less than 3 years of experience was slightly higher in the control arm.
 246 Among included patients, there were slightly more female patients and median age was slightly
 247 higher in intervention arm compared to control. Within the intervention arm, ePOCT+ was used
 248 throughout the whole consultation in 213/225 (95%) of consultations, partially used in 5/225 (2%),
 249 used after the consultation in 6/225 (3%), and not used at all in 1/225 (0.4%) of consultations.

250 **Table 1. Characteristics of health facilities, healthcare providers, and patients**

Characteristics of health facilities		Control (N=9)	Intervention (N=9)
<i>Type of facility</i>	Dispensary n (%)	5 (56%)	5 (56%)
	Health Centre n (%)	4 (44%)	4 (44%)
<i>Geographical distribution</i>	Urban n (%)	4 (44%)	3 (33%)
	Rural n (%)	5 (56%)	6 (67%)
<i>Region</i>	Mbeya n (%)	4 (44%)	4 (44%)
	Morogoro n (%)	5 (56%)	5 (56%)
Characteristics of healthcare providers		Control (N=17)	Intervention(N=22)
<i>Sex</i>	Female n (%)	9 (53%)	9 (41%)
	Male n (%)	8 (47%)	13 (59%)
<i>Age</i>	Years (Median; IQR)	32 (28,36)	34 (30,38)
	20- <30 years n (%)	5 (29%)	4 (18%)
<i>Experience*</i>	30- <40 years n (%)	9 (53%)	14 (64%)
	40- <50 years n (%)	2 (12%)	3 (14%)
	50- <60 years n (%)	1 (6%)	1 (5%)
	<= 3 years	7 (41%)	6 (27%)
	3- 5 years	3 (18%)	6 (27%)
	5 – 10 years	3 (18%)	6 (27%)
<i>Cadre</i>	>10 years	4 (24%)	4 (18%)
	Medical Doctor	3 (18%)	4 (18%)
	Assistant Medical Officer	1 (6%)	1 (5%)

	Clinical Officer	9 (53%)	10 (46%)
	Clinical Assistant	0 (0%)	1 (5%)
	Registered or Enrolled Nurse	4 (24%)	4 (18%)
	Medical Attendant	0 (0%)	2 (9%)
Characteristics of patients		Control (N=225)	Intervention (N=225)
Sex	Female n (%)	108 (48%)	123 (55%)
	Male n (%)	117 (52%)	102 (45%)
Age	Months (Median; IQR)	14 (7,28)	19 (9,31)
	2-11 months n (%)	98 (44%)	69 (31%)
	12-23 months n (%)	54 (24%)	72 (32%)
	24-35 months n (%)	33 (15%)	36 (16%)
	36- 47 months n (%)	24 (11%)	26 (12%)
	48-59 months n (%)	16 (7%)	22 (10%)

251 IQR: Inter-quartile range;

252 * Experience: Years of working experience

253

254 Fig 2. Health facility and patient flow diagram

255

256 Assessment of symptoms and signs, and counselling

257 The primary outcome of mean proportion of major IMCI symptoms and signs assessed was higher by
 258 an adjusted difference of 15.1% (95% confidence interval [CI] 4.8% to 25.4%), p-value 0.007) in
 259 intervention health facilities (mean of 46.4%, range 7.7% to 91.7%) compared to control health
 260 facilities (mean of 26.3%, range 0% to 66.7%) (table 2). Weight, mid-upper arm circumference
 261 (MUAC) and pallor were the only individual assessments among the pre-identified major IMCI
 262 symptoms and signs that showed a statistically significant difference in the adjusted risk ratio (table
 263 2). Among other symptoms and signs assessed, there was a statistically significant difference in the
 264 proportion of patients for which duration of cough, duration of diarrhea, mother's HIV status were
 265 assessed, and the proportion of children who were undressed for the physical examination (table 3).
 266 There was no statistical difference in the proportion of counselling topics covered by health
 267 providers between study arms (table 4). For most outcomes the intraclass correlation coefficient
 268 (ICC) was relatively high suggesting high variability in adherence to IMCI between health facilities.
 269 For the primary outcome of major IMCI symptoms and signs assessed, the ICC was higher in
 270 intervention health facilities (0.608) compared to control health facilities (0.354). This difference can

271 also be seen when visualizing the mean proportion of major IMCI symptoms and signs assessed from
 272 each health facility in a scatterplot (Figure 3).

273

274 **Table 2. Major IMCI Symptoms and Signs Assessed**

Primary Outcome	Control, mean % (range)	Intervention, mean % (range)	Intraclass correlation coefficient	Adjusted mean difference with 95% CI ^a	p-value
Primary outcome					
Major IMCI Symptoms and Signs	26.3% (0%; 66.7%)	46.4% (7.7%; 91.7%)	0.652	15.1% (4.8%; 25.4%)	0.007
Secondary Outcome	Control, n/N ^a (%)	Intervention, n/N ^b (%)	Intraclass correlation coefficient	Adjusted risk ratio with 95% CI ^a	p-value
IMCI Symptoms assessed:					
Convulsions in this illness ^b	16/225 (7.1%)	75/225 (33.3%)	0.442	2.1 (0.6; 7.0)	0.208
Unable to drink or breastfeed ^b	47/225 (20.9%)	107/225 (47.6%)	0.275	2.3 (0.8; 6.4)	0.109
Vomiting everything ^b	41/225 (18.2%)	81/225 (36.0%)	0.524	1.7 (0.5; 5.9)	0.363
Fever	196/225 (87.1%)	204/225 (90.7%)	0.060	1.0 (1.0; 1.14)	0.342
Cough or difficulty breathing	188/225 (83.6%)	189/225 (84.0%)	0.098	1.0 (0.9; 1.2)	0.847
Diarrhea	111/225 (49.3%)	130/225 (57.8%)	0.289	1.1 (0.5; 2.4)	0.872
Ear problem	11/225 (4.9%)	37/225 (16.4%)	0.504	1.0 (0.3; 3.5)	0.951
IMCI Signs assessed					
Weight	38/225 (16.9%)	128/225 (56.9%)	0.582	4.9 (1.9; 12.9)	0.004
Height	1/225 (0.4%)	3/225 (1.3%)	0.059	0.3 (0.1; 2.1)	0.225
MUAC	4/195 (2.1%)	131/202 (64.9%)	0.719	5.5 (1.7; 17.6)	0.008
Temperature	95/225 (42.2%)	148/225 (65.8%)	0.586	1.9 (0.6; 5.6)	0.227
Pallor	13/225 (5.8%)	72/225 (32.0%)	0.324	4.1 (1.6; 10.4)	0.005
Respiratory rate	15/182 (8.2%)	47/164 (28.7%)	0.280	1.9 (0.6; 6.1)	0.230
Skin turgor	4/153 (2.6%)	16/141 (11.4%)	0.142	2.1 (0.9; 5.0)	0.087

275 CI: Confidence interval; MUAC: Mid-upper arm circumference

276 ^aThe differences and relative risk were adjusted by type of health facility, council, healthcare worker cadre,
 277 healthcare worker years of experience, patient age and sex;

278 ^bDenominator based on patients for which this sign is clinically indicated to measure, i.e. for MUAC only
 279 children age 6 months and above, for respiratory rate only patients for which cough or difficulty is present or
 280 not asked, etc;

281 ^cIMCI Danger sign

282

283 **Fig 3. Scatter-plot of the mean proportion of the major IMCI symptoms and signs assessed**

284

285

286 **Table 3. Other Symptoms and Signs Assessed**

Symptoms & signs assessed	Control, n/N (%)	Intervention, n/N (%)	Intraclass correlation coefficient	Adjusted risk ratio with 95% CI ^a	p-value
Lethargic or Unconscious ^b	8/225 (3.6%)	14/225 (6.2%)	0.086	1.4 (0.6, 3.3)	0.476
Duration of fever ^c	96/147 (65.3%)	141/166 (84.9%)	0.176	1.6 (0.9, 2.6)	0.086
Duration of cough ^c	87/145 (60.0%)	110/128 (85.9%)	0.103	1.7 (1.1, 2.6)	0.021
Duration of diarrhea ^c	28/39 (71.8%)	43/46 (93.5%)	0.107	1.3 (1.0, 1.6)	0.036
Mother's HIV status	5/225 (2.2%)	162/225 (72.0%)	0.701	11.5 (4.1, 32.5)	0.002
Tuberculosis household contact	2/225 (0.9%)	60/225 (26.7%)	0.422	1.9 (0.5, 7.7)	0.361
Neck stiffness	2/147 (1.4%)	2/166 (1.2%)	0.010	n/a ^d	
Felt behind ear ^c	1/4 (25.0%)	2/3 (66.7%)	n/a	n/a ^d	
Looked in mouth	4/225 (1.8%)	20/225 (8.9%)	0.305	1.9 (0.5, 7.7)	0.363
Pulse oximetry	n/a	24/164 (14.6%)	0.717	n/a	
Lung auscultation	26/183 (14.2%)	15/164 (9.2%)	0.235	1.6 (0.5, 5.1)	0.373
Undressed the child	43/225 (19.1%)	99/225 (44.0%)	0.379	3.4 (1.4; 8.3)	0.011
Checked health card	68/225 (30.2%)	89/225 (39.6%)	0.552	1.5 (0.5, 5.0)	0.465

287 CI: Confidence interval; HIV: Human Immunodeficiency Virus; n/a: not applicable

288 ^aThe risk ratio was adjusted by type of health facility, council, healthcare worker cadre, healthcare worker
289 years of experience, patient age and sex;

290 ^bIMCI Danger sign

291 ^cDenominator based on patients for which clinically relevant to assess, i.e. duration of fever in those with
292 reported fever; duration of cough/difficulty breathing, pulse oximetry or lung auscultation in those with cough
293 or difficult breathing; duration of diarrhea in those with diarrhea; felt behind ear in those with an ear problem;
294 neck stiffness in those with fever;

295 ^dAdjusted risk ratio not calculated when fewer than 5 events

296

297

298 **Table 4. Counselling**

Counselling topic	Control, n/N (%)	Intervention, n/N (%)	Intraclass correlation coefficient	Adjusted risk ratio with 95% CI ^a	p-value
Informed diagnosis	92/225 (40.9%)	105/225 (46.7%)	0.454	1.4 (0.5, 4.0)	0.557
Feeding habit when not ill	40/225 (17.8%)	33/225 (14.7%)	0.427	0.7 (0.2, 2.7)	0.609
Feeding when not ill	32/225 (14.2%)	27/225 (12.0%)	0.258	0.7 (0.2, 1.8)	0.391
Extra fluids during current illness	12/225 (5.3%)	21/225 (9.3%)	0.198	1.2 (0.4, 4.0)	0.748
Continue feeding and breastfeeding when ill	25/225 (11.1%)	33/225 (14.7%)	0.292	1.0 (0.3, 3.1)	0.987
Danger signs to return to health facility	13/225 (5.8%)	17/225 (7.6%)	0.152	0.6 (0.2, 1.3)	0.182
Discussed growth chart	14/225 (6.2%)	15/225 (6.7%)	0.206	1.1 (0.3, 4.0)	0.826
Discuss follow up visit	18/225 (8.0%)	8/225 (3.6%)	0.052	0.9 (0.4, 2.1)	0.703
Opportunity to ask questions	87/225 (38.7%)	122/225 (54.2%)	0.717	1.0 (0.2, 4.9)	0.998

299 CI: Confidence interval

300 ^aThe relative risk was adjusted by type of health facility, council, healthcare worker cadre, healthcare worker
301 years of experience, patient age and sex;

302

303 **Antibiotic and antimalarial prescription**

304 Antibiotic prescription as observed by the external clinical researcher was lower in intervention
 305 health facilities compared to control health facilities with an adjusted risk ratio of 0.5, 95%CI 0.4 to
 306 0.7 p-value <0.001 (table 5). The documented antibiotic prescription by healthcare providers (in the
 307 ePOCT+ tool for intervention facilities, and eCRF in control facilities) during the same 5-week period
 308 collected by the external clinical researchers in the same health facilities of the present analysis, was
 309 slightly lower than that observed by the external clinical researchers. The adjusted risk ratio
 310 remained nonetheless similar, 0.4, 95% CI 0.2 to 0.7, p-value 0.005.

311
 312 81.9% of antibiotic prescriptions were appropriate in the intervention arm, compared to 51.4% in
 313 the control arm, adjusted relative risk of 1.5, 95% CI 1.2-1.5, p-value 0.003. All patients with malaria
 314 appropriately received an antimalarial treatment, and no patient without malaria received an
 315 antimalarial in both study arms.

316

317 **Table 5. Antibiotic prescription and appropriate antibiotic and antimalarial prescription**

	Control (N=225)	Intervention (N=225)	Intraclass correlation coefficient	Adjusted risk ratio with 95% CI	p- value
Antibiotic prescription as observed by external clinical researchers	172/225 (76.4%)	84/225 (37.3%)	0.146	0.5 (0.4, 0.7)	<0.001
Antibiotic prescription as reported in ePOCT+ or eCRF by health providers ^{ab}	162/239 (67.8%)	90/294 (30.6%)	0.214	0.4 (0.2, 0.7)	0.005
Appropriate antibiotic prescription	112/218 (51.4%)	158/193 (81.9%)	0.165	1.5 (1.2; 1.8)	0.003
Appropriate antimalarial prescription	2/2 (100%)	30/30 (100%)	n/a	n/a	n/a

318 ^aAntibiotic prescription among new cases in patients aged 2-59 months, where antibiotic prescription was
 319 documented during the same days and same health facilities as the ancillary study;

320 ^bAnalysis performed using the same model including the same individual and cluster level adjustment factors,
 321 except for those related to the health providers (education, and cadre)

322

323

324 **Discussion**

325 This cluster randomized controlled trial in Tanzania found that the use of ePOCT+, a digital clinical
326 decision support algorithm, for the management of sick children aged 2-59 months old, moderately
327 increased (by 15%) the mean proportion of major IMCI symptoms and signs assessed by health
328 providers in primary care level health facilities. The overall proportion of IMCI symptoms and signs
329 assessed at each individual consultation however remained low.

330 The overall increase in the mean proportion of major IMCI symptom and signs assessed by health
331 providers aligns with previous studies in Tanzania [13], Afghanistan [36], Nigeria [17], and Burkina
332 Faso [16], but in contrast to findings in South Africa [15], that did not find improvements in the
333 assessment of IMCI symptoms and signs. While these findings suggest that digital clinical decision
334 support algorithms can positively enhance quality of care for sick children, there is much room for
335 improvement. Indeed, the proportion of most individual IMCI symptoms and signs assessed in both
336 control and intervention arms were low, much lower than previous studies, and many symptoms
337 and signs were not assessed more frequently in intervention health facilities. Differences compared
338 to other studies, may be explained by the more pragmatic nature of the study compared to other
339 studies conducted in more controlled settings (shorter pilot studies) where the Hawthorne effect
340 may have a greater influence on health care provider behavior [13]. In addition, our study found
341 much worse adherence to IMCI in the control arm compared to most other similar studies, such
342 differences could partly be explained by differences in the setting and healthcare providers, notably
343 the frequency and type of IMCI training provided to healthcare providers [16, 17]. The low
344 proportion of children assessed for danger signs to identify children at highest risk of mortality is
345 most concerning (33% for convulsions, 48% for unable to drink or breastfeed, and 36% for vomiting
346 everything in the intervention arm). Respiratory rate was also infrequently assessed (29% in
347 intervention arm), despite being an essential sign to distinguish children with cough or difficulty
348 breathing requiring antibiotics or not [29].

349 The statistically significant increase in the assessment of weight (aRR 4.9 [95% CI 1.9 to 12.9]), and
350 MUAC (aRR 5.5 [95% CI 1.7 to 17.6]) is noteworthy, as they are critical anthropometric measures to
351 identify children with malnutrition, a condition that contributes significantly to childhood morbidity
352 and mortality. Systematically measuring weight and MUAC to identify and manage severe
353 malnutrition can indeed improve clinical outcomes as well as the long term health status of children
354 [41]. The low proportion of children assessed for height/length however, reflects the difficulty and
355 constraints of this measurement in particular [42], and the impact of not requiring the measurement
356 to be mandatory within the digital tool.

357 While improved adherence to the assessment of IMCI symptoms and signs would likely be beneficial,
358 translation to improved clinical outcomes should not automatically be assumed. Health providers
359 often integrate a number of clinical cues that may allow them to distinguish which child would truly
360 require danger signs to be assessed, or respiratory rate to be measured. For example, a 2 year old
361 child presenting to a primary care health facility smiling and playing in the consultation room, with
362 complaints of cough and runny nose for the past 2 days without difficulty breathing or fever, is
363 unlikely to have danger signs and very often not have fast breathing or chest indrawing. This raises
364 the important question on how to best assess quality of care, and whether it can be done without
365 assessment of clinical outcome.

366 The large variation in mean proportion of major IMCI symptoms and signs between intervention
367 health facilities provide clues to higher potential benefits of the intervention. The three best health
368 facilities have a mean score of 60% or above, and the three worst below 30%. While clinical decision
369 support algorithms may help improve knowledge and information on what symptoms and signs to
370 assess, it would not address the other barriers and bad habits linked to poor adherence to IMCI [9,
371 10]. As with many complex health interventions, implementation of new interventions, and or
372 guidelines may often not succeed with training alone, instead meaningful mentorship must be
373 accompanied [43]. Indeed training, mentorship, and dashboards integrating benchmarking were part

374 of the current intervention package, however these supportive interventions were not targeted
375 towards assuring adherence to the assessment of many IMCI symptoms and signs but rather
376 targeted on antibiotic stewardship, and overall uptake on the use of the tools. Adaptations to these
377 supportive tools to target specific IMCI quality of care measures may help [44-46]. Further
378 qualitative investigations are underway to better understand healthcare provider perspectives on
379 barriers in adhering to ePOCT+ and the IMCI chartbook.

380 The study also revealed a two-fold reduction in antibiotic prescriptions (adjusted relative risk 0.5,
381 95% CI 0.4 to 0.7), and 50% improvement in the appropriate use of antibiotics in health facilities
382 using ePOCT+ (adjusted relative risk 1.5 (95% CI 1.2 to 1.8), critical findings given the global concern
383 for bacterial antimicrobial resistance [47]. Similar reductions were found in the parent trial using the
384 intention-to-treat results over the full 11 month trial period (adjusted relative risk 0.6 (95% CI 0.5 to
385 0.6),[24] and in the same 5-week period as the present trial (adjusted relative risk 0.4, 95% CI 0.2 to
386 0.7). However, the documented antibiotic prescription as observed by external clinical researchers
387 was slightly higher than what was documented by the health providers in ePOCT+ (intervention
388 health facilities) and the eCRF (control health facilities), suggesting that some health providers may
389 under report antibiotic prescription in ePOCT+ and the eCRF.

390 There were several limitations to this study. First, the Hawthorne effect, the presence of an external
391 clinical researcher observing the consultation may have influenced the healthcare provider's practice
392 in both study arms. Indeed the uptake of the ePOCT+ tool in this study was higher compared to the
393 parent trial (95% versus 76%), likely due to the presence of the researchers. Despite this, adherence
394 to the IMCI chartbook was relatively low, and substantially lower compared to other studies,
395 suggesting that the Hawthorne effect may not have had such a big impact, and the desirability bias
396 minimal. Second, sample size; while the study was sufficiently powered for the primary outcome,
397 interpretation of the secondary outcomes would have benefited from a higher sample size. Indeed
398 many secondary outcomes did not show statistical significance despite relatively high effect size,

399 likely due to the higher than expected heterogeneity between health facilities as indicated by the
400 high ICC. Third, the intervention package included not only the digital tool, but also mentorship and
401 benchmarking quality of care dashboards. It is thus not possible to understand what part of the
402 intervention package and to what extent, impacted quality of care. Finally as discussed in previous
403 paragraphs, adherence to IMCI is an imperfect proxy for the measurement of quality of care.

404

405 In conclusion, a digital clinical decision support algorithm package can help improve quality of care,
406 however adherence to IMCI remained low for many symptoms and signs in a close to real world
407 assessment. Further efforts including innovative approaches to improve quality of care are highly
408 needed. The implementation of multiple interventions, such as the development and improvement
409 of supportive mentorship of clinicians, better healthcare provider incentives, task-shifting, ongoing
410 training and performance accountability may help address the many barriers to quality of care.

411

412 **Acknowledgments**

413 We would like to first thank all the participating healthcare providers, patients and caregivers. We
414 acknowledge the contributions of the research assistants at the Ifakara Health Institute and Mbeya
415 Medical Research Centre – National Institute of Medical Research, who assisted in the data
416 collection, the Information Technology staff at Unisanté (Sylvain Schaufelberger, Greg Martin), and
417 staff at Wavemind (Emmanuel Barchichat, Alain Fresco, and Quentin Girard) for their work on the
418 medAL-suite during the study, and Community Health Management Team members in the 5
419 participating councils in Tanzania for their collaboration in implementing the study. We acknowledge
420 researchers of the Tools of Integrated Management of Childhood Illness and DYNAMIC Rwanda
421 project for their contributions to ePOCT+ and the many common research activities (Dr Fenella
422 Beynon, Dr Lena Matata, Dr Helene Langet, Dr Ludovico Cobuccio, Dr Victor Rwandacu, Dr Robert

423 Moshiro). Finally we would like to acknowledge the work of Dr Irene Masanja on the initial
424 development of the study, who regretablely passed away before the start of the study.
425

426 **References**

- 427 1. Kruk ME, Gage AD, Joseph NT, Danaei G, García-Saisó S, Salomon JA. Mortality due to low-
428 quality health systems in the universal health coverage era: a systematic analysis of amenable
429 deaths in 137 countries. *The Lancet*. 2018;392(10160):2203-12. doi: 10.1016/S0140-6736(18)31668-
430 4.
- 431 2. Di Giorgio L, Evans DK, Lindelow M, Nguyen SN, Svensson J, Wane W, et al. Analysis of
432 clinical knowledge, absenteeism and availability of resources for maternal and child health: a cross-
433 sectional quality of care study in 10 African countries. *BMJ Glob Health*. 2020;5(12). Epub
434 2020/12/24. doi: 10.1136/bmjgh-2020-003377. PubMed PMID: 33355259; PubMed Central PMCID:
435 PMC7751199.
- 436 3. Kruk ME, Gage AD, Arsenaault C, Jordan K, Leslie HH, Roder-DeWan S, et al. High-quality
437 health systems in the Sustainable Development Goals era: time for a revolution. *The Lancet Global*
438 *Health*. 2018;6(11):e1196-e252. doi: [https://doi.org/10.1016/S2214-109X\(18\)30386-3](https://doi.org/10.1016/S2214-109X(18)30386-3).
- 439 4. World Health Organization. *World Health Report, Working Together for Health*. Geneva:
440 World Health Organization; 2006.
- 441 5. World Health Organization. *Integrated Management of Childhood Illness Chartbook*. Geneva:
442 2014.
- 443 6. Boschi-Pinto C, Labadie G, Dilip TR, Oliphant N, L. Dalglish S, Aboubaker S, et al. Global
444 implementation survey of Integrated Management of Childhood Illness (IMCI): 20 years on. *BMJ*
445 *open*. 2018;8(7):e019079. doi: 10.1136/bmjopen-2017-019079.
- 446 7. Gera T, Shah D, Garner P, Richardson M, Sachdev HS. Integrated management of childhood
447 illness (IMCI) strategy for children under five. *Cochrane Database Syst Rev*. 2016;(6):Cd010123. Epub
448 2016/07/06. doi: 10.1002/14651858.CD010123.pub2. PubMed PMID: 27378094; PubMed Central
449 PMCID: PMC4943011.
- 450 8. Krüger C, Heinzl-Gutenbrunner M, Ali M. Adherence to the integrated management of
451 childhood illness guidelines in Namibia, Kenya, Tanzania and Uganda: evidence from the national
452 service provision assessment surveys. *BMC Health Serv Res*. 2017;17(1):822. Epub 2017/12/15. doi:
453 10.1186/s12913-017-2781-3. PubMed PMID: 29237494; PubMed Central PMCID: PMC5729502.
- 454 9. Kiplagat A, Musto R, Mwizamholya D, Morona D. Factors influencing the implementation of
455 integrated management of childhood illness (IMCI) by healthcare workers at public health centers &
456 dispensaries in Mwanza, Tanzania. *BMC public health*. 2014;14:277. Epub 2014/03/29. doi:
457 10.1186/1471-2458-14-277. PubMed PMID: 24666561; PubMed Central PMCID: PMC3987128.
- 458 10. Lange S, Mwisongo A, Mæstad O. Why don't clinicians adhere more consistently to
459 guidelines for the Integrated Management of Childhood Illness (IMCI)? *Soc Sci Med*. 2014;104:56-63.
460 Epub 2014/03/04. doi: 10.1016/j.socscimed.2013.12.020. PubMed PMID: 24581062.
- 461 11. Beynon F, Guérin F, Lampariello R, Schmitz T, Tan R, Ratanaprayul N, et al. Digitalizing Clinical
462 Guidelines: Experiences in the Development of Clinical Decision Support Algorithms for Management
463 of Childhood Illness in Resource-Constrained Settings. *Global Health: Science and Practice*. 2023.
- 464 12. Keitel K, D'Acremont V. Electronic clinical decision algorithms for the integrated primary care
465 management of febrile children in low-resource settings: review of existing tools. *Clinical*
466 *microbiology and infection : the official publication of the European Society of Clinical Microbiology*

- 467 and Infectious Diseases. 2018;24(8):845-55. Epub 2018/04/24. doi: 10.1016/j.cmi.2018.04.014.
468 PubMed PMID: 29684634.
- 469 13. Mitchell M, Hedt-Gauthier BL, Msellemu D, Nkaka M, Lesh N. Using electronic technology to
470 improve clinical care - results from a before-after cluster trial to evaluate assessment and
471 classification of sick children according to Integrated Management of Childhood Illness (IMCI)
472 protocol in Tanzania. BMC medical informatics and decision making. 2013;13:95. Epub 2013/08/29.
473 doi: 10.1186/1472-6947-13-95. PubMed PMID: 23981292; PubMed Central PMCID:
474 PMCPMC3766002.
- 475 14. Rambaud-Althaus C, Shao A, Samaka J, Swai N, Perri S, Kahama-Maró J, et al. Performance of
476 Health Workers Using an Electronic Algorithm for the Management of Childhood Illness in Tanzania:
477 A Pilot Implementation Study. The American journal of tropical medicine and hygiene.
478 2017;96(1):249-57. Epub 2017/01/13. doi: 10.4269/ajtmh.15-0395. PubMed PMID: 28077751;
479 PubMed Central PMCID: PMCPMC5239703.
- 480 15. Horwood C, Haskins L, Mapumulo S, Connolly C, Luthuli S, Jensen C, et al. Electronic
481 Integrated Management of Childhood Illness (eIMCI): a randomized controlled trial to evaluate an
482 electronic clinical decision-making support system for management of sick children in primary health
483 care facilities in South Africa. 2023. doi: 10.21203/rs.3.rs-2746877/v1.
- 484 16. Sarrasat S, Lewis JJ, Some AS, Somda S, Cousens S, Blanchet K. An Integrated eDiagnosis
485 Approach (IeDA) versus standard IMCI for assessing and managing childhood illness in Burkina Faso:
486 a stepped-wedge cluster randomised trial. BMC health services research. 2021;21(1):354-. doi:
487 10.1186/s12913-021-06317-3. PubMed PMID: 33863326.
- 488 17. Bernasconi A, Crabbé F, Adedeji AM, Bello A, Schmitz T, Landi M, et al. Results from one-year
489 use of an electronic Clinical Decision Support System in a post-conflict context: An implementation
490 research. PLoS One. 2019;14(12):e0225634. Epub 2019/12/04. doi: 10.1371/journal.pone.0225634.
491 PubMed PMID: 31790448; PubMed Central PMCID: PMCPMC6886837.
- 492 18. Bernasconi A, Crabbé F, Rossi R, Qani I, Vanobberghen A, Raab M, et al. The ALMANACH
493 Project: Preliminary results and potentiality from Afghanistan. International journal of medical
494 informatics. 2018;114:130-5.
- 495 19. Beynon F, Salzmán T, Faye PM, Thiongane A, Ndiaye O, Luwanda LB, et al. Paediatric digital
496 clinical decision support for global health. Revue Medicale Suisse. 2023;19(836):1398-403.
- 497 20. Agarwal S, Glenton C, Tamrat T, Henschke N, Maayan N, Fønhus MS, et al. Decision-support
498 tools via mobile devices to improve quality of care in primary healthcare settings. Cochrane
499 Database Syst Rev. 2021;7(7):Cd012944. Epub 2021/07/28. doi: 10.1002/14651858.CD012944.pub2.
500 PubMed PMID: 34314020; PubMed Central PMCID: PMCPMC8406991.
- 501 21. Rambaud-Althaus C, Shao AF, Kahama-Maró J, Genton B, d'Acremont V. Managing the Sick
502 Child in the Era of Declining Malaria Transmission: Development of ALMANACH, an Electronic
503 Algorithm for Appropriate Use of Antimicrobials. PLoS One. 2015;10(7):e0127674. Epub 2015/07/15.
504 doi: 10.1371/journal.pone.0127674. PubMed PMID: 26161753; PubMed Central PMCID:
505 PMCPMC4498609.
- 506 22. Keitel K, Kagoro F, Samaka J, Masimba J, Said Z, Temba H, et al. A novel electronic algorithm
507 using host biomarker point-of-care tests for the management of febrile illnesses in Tanzanian
508 children (e-POCT): A randomized, controlled non-inferiority trial. PLoS medicine.

- 509 2017;14(10):e1002411. Epub 2017/10/24. doi: 10.1371/journal.pmed.1002411. PubMed PMID:
510 29059253; PubMed Central PMCID: PMC5653205.
- 511 23. Tan R, Cobuccio L, Beynon F, Levine GA, Vaezipour N, Luwanda LB, et al. ePOCT+ and the
512 medAL-suite: Development of an electronic clinical decision support algorithm and digital platform
513 for pediatric outpatients in low- and middle-income countries. PLOS Digital Health.
514 2023;2(1):e0000170. doi: 10.1371/journal.pdig.0000170.
- 515 24. Tan R, Kavishe G, Luwanda LB, Kulinkina AV, Renggli S, Mangu C, et al. A digital health
516 algorithm to guide antibiotic prescription in pediatric outpatient care: a cluster randomized
517 controlled trial. Nature Medicine. 2023. doi: 10.1038/s41591-023-02633-9.
- 518 25. Shao AF, Rambaud-Althaus C, Samaka J, Faustine AF, Perri-Moore S, Swai N, et al. New
519 Algorithm for Managing Childhood Illness Using Mobile Technology (ALMANACH): A Controlled Non-
520 Inferiority Study on Clinical Outcome and Antibiotic Use in Tanzania. PLoS One.
521 2015;10(7):e0132316. Epub 2015/07/15. doi: 10.1371/journal.pone.0132316. PubMed PMID:
522 26161535; PubMed Central PMCID: PMC4498627.
- 523 26. Tanzania Commission for AIDS (TACAIDS), (ZAC) ZAC. Tanzania HIV Impact Survey (THIS)
524 2016-2017: Final Report. Dar es Salaam, Tanzania 2018.
- 525 27. Amu H, Dickson KS, Kumi-Kyereme A, Darteh EKM. Understanding variations in health
526 insurance coverage in Ghana, Kenya, Nigeria, and Tanzania: Evidence from demographic and health
527 surveys. PLoS One. 2018;13(8):e0201833. doi: 10.1371/journal.pone.0201833.
- 528 28. Mullan F, Frehywot S. Non-physician clinicians in 47 sub-Saharan African countries. The
529 Lancet. 2007;370(9605):2158-63. doi: [https://doi.org/10.1016/S0140-6736\(07\)60785-5](https://doi.org/10.1016/S0140-6736(07)60785-5).
- 530 29. World Health Organization. Integrated Management of Childhood Illness Chart Booklet.
531 Geneva: 2014 2014. Report No.
- 532 30. World Health Organization. Pocket Book of Hospital Care for Children: Guidelines for the
533 Management of Common Childhood Illnesses. 2nd ed. Geneva: World Health Organization; 2013.
- 534 31. Demographic and Health Surveys (DHS). Service Provision Assessments (SPA) 2024 [cited
535 2024 05.02.2024]. Available from: <https://dhsprogram.com/Methodology/Survey-Types/SPA.cfm>.
- 536 32. Gilroy K, Winch PJ, Diawara A, Swedberg E, Thiéro F, Kané M, et al. Impact of IMCI training
537 and language used by provider on quality of counseling provided to parents of sick children in
538 Bougouni District, Mali. Patient Education and Counseling. 2004;54(1):35-44. doi:
539 [https://doi.org/10.1016/S0738-3991\(03\)00189-7](https://doi.org/10.1016/S0738-3991(03)00189-7).
- 540 33. Rowe AK, Onikpo F, Lama M, Osterholt DM, Rowe SY, Deming MS. A multifaceted
541 intervention to improve health worker adherence to integrated management of childhood illness
542 guidelines in Benin. Am J Public Health. 2009;99(5):837-46. Epub 2009/03/19. doi:
543 10.2105/AJPH.2008.134411. PubMed PMID: 19299681.
- 544 34. Lemiengre MB, Verbakel JY, Colman R, De Burghgraeve T, Buntinx F, Aertgeerts B, et al.
545 Reducing inappropriate antibiotic prescribing for children in primary care: a cluster randomised
546 controlled trial of two interventions. The British journal of general practice : the journal of the Royal
547 College of General Practitioners. 2018;68(668):e204-e10. Epub 2018/02/12. doi:
548 10.3399/bjgp18X695033. PubMed PMID: 29440016.

- 549 35. Flottorp S, Oxman AD, Håvelsrud K, Treweek S, Herrin J. Cluster randomised controlled trial
550 of tailored interventions to improve the management of urinary tract infections in women and sore
551 throat. *BMJ*. 2002;325(7360):367. doi: 10.1136/bmj.325.7360.367.
- 552 36. Bernasconi A, Crabbé F, Raab M, Rossi R. Can the use of digital algorithms improve quality
553 care? An example from Afghanistan. *PLoS One*. 2018;13(11):e0207233-e. doi:
554 10.1371/journal.pone.0207233. PubMed PMID: 30475833.
- 555 37. Tan R, Kavishe G, Kulinkina A, Luwanda L, Renggli S, Mangu C, et al. Antibiotic stewardship
556 using ePOCT+, a digital health clinical decision support algorithm for paediatric outpatient care:
557 results from the DYNAMIC Tanzania cluster randomized controlled trial. *Research Square* (pre-print).
558 2023. doi: 10.21203/rs.3.rs-3084190/v1.
- 559 38. Thompson JA, Leyrat C, Fielding KL, Hayes RJ. Cluster randomised trials with a binary
560 outcome and a small number of clusters: comparison of individual and cluster level analysis method.
561 *BMC Medical Research Methodology*. 2022;22(1):1-15.
- 562 39. Hayes RJ, Moulton LH. *Cluster randomised trials*: CRC press; 2017.
- 563 40. Thompson JA, Leurent B, Nash S, Moulton LH, Hayes RJ. Cluster randomized controlled trial
564 analysis at the cluster level: The clan command. *The Stata Journal*. 2023;23(3):754-73.
- 565 41. Tan R, Kagoro F, Levine GA, Masimba J, Samaka J, Sangu W, et al. Clinical Outcome of Febrile
566 Tanzanian Children with Severe Malnutrition Using Anthropometry in Comparison to Clinical Signs.
567 *American Journal of Tropical Medicine and Hygiene*. 2020;102(2):427-35. doi: 10.4269/ajtmh.19-
568 0553. PubMed PMID: WOS:000512881500035.
- 569 42. Myatt M, Khara T, Collins S. A Review of Methods to Detect Cases of Severely Malnourished
570 Children in the Community for Their Admission into Community-Based Therapeutic Care Programs.
571 *Food and Nutrition Bulletin*. 2006;27(3_suppl3):S7-S23. doi: 10.1177/15648265060273S302.
- 572 43. Oxman AD, Thomson MA, Davis DA, Haynes RB. No magic bullets: a systematic review of 102
573 trials of interventions to improve professional practice. *CMAJ : Canadian Medical Association journal*
574 = *journal de l'Association medicale canadienne*. 1995;153(10):1423-31. Epub 1995/11/15. PubMed
575 PMID: 7585368; PubMed Central PMCID: PMCPMC1487455.
- 576 44. Odendaal WA, Anstey Watkins J, Leon N, Goudge J, Griffiths F, Tomlinson M, et al. Health
577 workers' perceptions and experiences of using mHealth technologies to deliver primary healthcare
578 services: a qualitative evidence synthesis. *Cochrane Database Syst Rev*. 2020;3(3):Cd011942. Epub
579 2020/03/28. doi: 10.1002/14651858.CD011942.pub2. PubMed PMID: 32216074; PubMed Central
580 PMCID: PMCPMC7098082.
- 581 45. Kruse C, Betancourt J, Ortiz S, Valdes Luna SM, Bamrah IK, Segovia N. Barriers to the Use of
582 Mobile Health in Improving Health Outcomes in Developing Countries: Systematic Review. *J Med*
583 *Internet Res*. 2019;21(10):e13263. Epub 2019/10/09. doi: 10.2196/13263. PubMed PMID: 31593543;
584 PubMed Central PMCID: PMCPMC6811771.
- 585 46. Renggli S, Mayumana I, Mboya D, Charles C, Maeda J, Mshana C, et al. Towards improved
586 health service quality in Tanzania: An approach to increase efficiency and effectiveness of routine
587 supportive supervision. *PLoS One*. 2018;13(9):e0202735. doi: 10.1371/journal.pone.0202735.

588 47. Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, et al. Global burden
589 of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet. 2022. doi:
590 10.1016/S0140-6736(21)02724-0.

591

592 **Supporting information**

593 **S1 File. DYNAMIC Tanzania study protocol**

594 **S2 File. Statistical analysis plan**

595 **S3 CONSORT Checklist**





Figure 1

Cluster-level information



Child-level information



Figure 2




Figure 3